Cost-Effectiveness Analysis of Lung Cancer Screening in the United States

医学 肺癌 癌症筛查 肺癌筛查 癌症 肿瘤科 重症监护医学 内科学
作者
Steven D. Criss,Harry J. de Koning,Sylvia K. Plevritis,Rafael Meza,Chung Yin Kong
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:172 (10): 706-707 被引量:5
标识
DOI:10.7326/l20-0072
摘要

Letters19 May 2020Cost-Effectiveness Analysis of Lung Cancer Screening in the United StatesSteven D. Criss, BS, Harry J. de Koning, MD, PhD, Sylvia K. Plevritis, PhD, Rafael Meza, PhD, and Chung Yin Kong, PhDSteven D. Criss, BSHarvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Search for more papers by this author, Harry J. de Koning, MD, PhDErasmus University Medical Center, Rotterdam, the Netherlands (H.J.D.)Search for more papers by this author, Sylvia K. Plevritis, PhDStanford University, Stanford, California (S.K.P.)Search for more papers by this author, Rafael Meza, PhDUniversity of Michigan, Ann Arbor, Michigan (R.M.)Search for more papers by this author, and Chung Yin Kong, PhDHarvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0072 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Young and Ms. Hopkins that the high prevalence of chronic obstructive pulmonary disease and other comorbidities among persons eligible for lung cancer screening limits the effectiveness of risk-based screening. The detection of lung cancer in patients who are ineligible for curative surgical treatment certainly attenuates the benefits of screening, as do the shorter life expectancy and higher rate of non–lung cancer deaths associated with comorbid disease. We also agree that it would be valuable for chronic obstructive pulmonary disease status to be part of conversations between patients and their physicians around the potential benefits ...References1. Chua GWY, Chua KLM. Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate. Thorac Cancer. 2019;10:1857-1867. [PMID: 31389163] doi:10.1111/1759-7714.13160 CrossrefMedlineGoogle Scholar2. Takeda A, Enomoto T, Sanuki N, et al. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest. 2013;143:130-137. [PMID: 22722234] doi:10.1378/chest.12-0207 CrossrefMedlineGoogle Scholar3. Warren GW, Alberg AJ, Kraft AS, et al. The 2014 Surgeon General's report: “The health consequences of smoking—50 years of progress”: a paradigm shift in cancer care [Editorial]. Cancer. 2014;120:1914-1916. [PMID: 24687615] doi:10.1002/cncr.28695 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Harvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Erasmus University Medical Center, Rotterdam, the Netherlands (H.J.D.)Stanford University, Stanford, California (S.K.P.)University of Michigan, Ann Arbor, Michigan (R.M.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0322. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness Analysis of Lung Cancer Screening in the United States Steven D. Criss , Pianpian Cao , Mehrad Bastani , Kevin ten Haaf , Yufan Chen , Deirdre F. Sheehan , Erik F. Blom , Iakovos Toumazis , Jihyoun Jeon , Harry J. de Koning , Sylvia K. Plevritis , Rafael Meza , and Chung Yin Kong Cost-Effectiveness Analysis of Lung Cancer Screening in the United States Robert P. Young and Raewyn J. Hopkins Metrics Cited byBlood-Based Biomarker Panel for Personalized Lung Cancer Risk AssessmentContemporary issues in the implementation of lung cancer screening 19 May 2020Volume 172, Issue 10Page: 706-707KeywordsCancer screeningCancer treatmentChronic obstructive pulmonary diseaseDisclosureLife expectancyLung and intrathoracic tumorsLung cancer screeningRespiratory system proceduresSurgeryType 2 diabetes ePublished: 19 May 2020 Issue Published: 19 May 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jiw发布了新的文献求助10
刚刚
hdh完成签到,获得积分10
刚刚
孤独听雨的猫完成签到 ,获得积分10
1秒前
licheng完成签到,获得积分10
1秒前
2秒前
MM完成签到,获得积分10
3秒前
我是老大应助fash采纳,获得10
3秒前
qc应助怪杰采纳,获得10
3秒前
汉堡包应助ZZZZCloud采纳,获得10
5秒前
Ssyong完成签到 ,获得积分10
5秒前
JT完成签到,获得积分10
6秒前
qiqi完成签到,获得积分10
6秒前
6秒前
丰富的慕卉完成签到,获得积分10
6秒前
阳光迎夏完成签到 ,获得积分10
6秒前
ID27149完成签到,获得积分10
8秒前
研友_n01QxZ完成签到,获得积分10
8秒前
科研小白完成签到,获得积分10
9秒前
9秒前
GOAT发布了新的文献求助10
9秒前
合适听白完成签到,获得积分20
10秒前
小马的可爱老婆完成签到,获得积分10
11秒前
花花发布了新的文献求助20
11秒前
bei完成签到,获得积分10
12秒前
暴躁的水蜜桃完成签到 ,获得积分10
13秒前
天仙狂醉完成签到 ,获得积分10
13秒前
bkagyin应助胡房晓采纳,获得10
13秒前
yliu完成签到,获得积分10
13秒前
14秒前
zhaosiqi完成签到 ,获得积分10
14秒前
充电宝应助badercao采纳,获得20
14秒前
JamesPei应助科研通管家采纳,获得10
15秒前
NexusExplorer应助科研通管家采纳,获得10
15秒前
慕青应助科研通管家采纳,获得10
15秒前
asdfqwer应助科研通管家采纳,获得10
15秒前
小马甲应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
15秒前
NexusExplorer应助科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 生物化学 化学工程 物理 计算机科学 复合材料 内科学 催化作用 物理化学 光电子学 电极 冶金 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6022031
求助须知:如何正确求助?哪些是违规求助? 7638908
关于积分的说明 16167722
捐赠科研通 5170058
什么是DOI,文献DOI怎么找? 2766661
邀请新用户注册赠送积分活动 1749784
关于科研通互助平台的介绍 1636740